Stonepine Capital Management is an investment fund managing more than $109 billion ran by Jon Plexico. There are currently 25 companies in Mr. Plexico’s portfolio. The largest investments include Adma Biologics Inc and Alimera Sciences, together worth $40.4 billion.
As of 6th August 2024, Stonepine Capital Management’s top holding is 1,870,000 shares of Adma Biologics Inc currently worth over $20.9 billion and making up 19.2% of the portfolio value.
Relative to the number of outstanding shares of Adma Biologics Inc, Stonepine Capital Management owns more than approximately 0.1% of the company.
In addition, the fund holds 3,511,816 shares of Alimera Sciences worth $19.5 billion, whose value grew 48.1% in the past six months.
The third-largest holding is Evolus Inc worth $18 billion and the next is Galapagos Nv-spon Adr worth $12 billion, with 485,000 shares owned.
Currently, Stonepine Capital Management's portfolio is worth at least $109 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Stonepine Capital Management office and employees reside in Bend, Oregon. According to the last 13-F report filed with the SEC, Jon Plexico serves as the Managing Member at Stonepine Capital Management.
In the most recent 13F filing, Stonepine Capital Management revealed that it had opened a new position in
Revance Therapeutics Inc and bought 2,800,000 shares worth $7.2 billion.
This means they effectively own approximately 0.1% of the company.
Revance Therapeutics Inc makes up
8.2%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Galapagos Nv-spon Adr by buying
223,130 additional shares.
This makes their stake in Galapagos Nv-spon Adr total 485,000 shares worth $12 billion.
On the other hand, there are companies that Stonepine Capital Management is getting rid of from its portfolio.
Stonepine Capital Management closed its position in Amylyx Pharmaceuticals Inc on 13th August 2024.
It sold the previously owned 2,500,000 shares for $36.8 billion.
Jon Plexico also disclosed a decreased stake in Adma Biologics Inc by 0.8%.
This leaves the value of the investment at $20.9 billion and 1,870,000 shares.
The two most similar investment funds to Stonepine Capital Management are Integrity Advisory and Euclidean Technologies Management. They manage $109 billion and $109 billion respectively.
Stonepine Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 80.2% of
the total portfolio value.
The fund focuses on investments in the United States as
68.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
20% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $581 million.
These positions were updated on August 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Amylyx Pharmaceuticals Inc |
Closed
2,500,000
|
$36,800,000,000 | |
| QuidelOrtho Corporation |
Closed
450,000
|
$33,165,000,000 | |
| Adma Biologics Inc |
79.72%
1,870,000
|
$20,906,600,000 | 19.20% |
| Alimera Sciences Inc. |
12.19%
3,511,816
|
$19,525,697,000 | 17.93% |
| Evolus Inc |
68.92%
1,657,611
|
$17,985,079,000 | 16.52% |
| Xeris Biopharma Holdings Inc |
Closed
5,937,000
|
$13,951,950,000 | |
| Galapagos Nv-spon Adr |
85.21%
485,000
|
$12,018,300,000 | 11.04% |
| Revance Therapeutics Inc |
Opened
2,800,000
|
$7,196,000,000 | 6.61% |
| Xoma Corp |
0.05%
250,129
|
$5,925,556,000 | 5.44% |
| Anika Therapeutics Inc. |
Opened
165,397
|
$4,189,506,000 | 3.85% |
| Io Biotech Inc |
Closed
1,666,037
|
$3,132,150,000 | |
| Scynexis Inc |
Closed
1,355,186
|
$3,022,065,000 | |
| TELA Bio, Inc. |
96.88%
625,645
|
$2,940,532,000 | 2.70% |
| Rezolute Inc |
Closed
2,768,656
|
$2,747,891,000 | |
| Atea Pharmaceuticals, Inc. |
Closed
839,514
|
$2,560,518,000 | |
| Rigel Pharmaceuticals |
Opened
305,000
|
$2,507,100,000 | 2.30% |
| OptiNose Inc |
Opened
2,350,010
|
$2,444,010,000 | 2.24% |
| Aclaris Therapeutics Inc |
Opened
1,927,446
|
$2,120,191,000 | 1.95% |
| scPharmaceuticals Inc |
Opened
421,703
|
$1,834,408,000 | 1.68% |
| Aurinia Pharmaceuticals Inc |
Opened
300,000
|
$1,713,000,000 | 1.57% |
| Milestone Pharmaceuticals In |
Opened
1,239,199
|
$1,635,743,000 | 1.50% |
| Aytu BioPharma Inc |
No change
472,469
|
$1,379,609,000 | 1.27% |
| Kiora Pharmaceuticals Inc |
Opened
200,000
|
$840,000,000 | 0.77% |
| Adicet Bio Inc |
Opened
609,446
|
$737,430,000 | 0.68% |
| Atyr Pharma Inc |
Closed
482,258
|
$679,984,000 | |
| Exagen Inc |
46.44%
358,697
|
$652,829,000 | 0.60% |
| Kezar Life Sciences Inc |
Opened
1,050,452
|
$630,271,000 | 0.58% |
| Aprea Therapeutics, Inc. |
Opened
137,174
|
$558,298,000 | 0.51% |
| 2seventy Bio Inc |
Opened
100,000
|
$385,000,000 | 0.35% |
| Eton Pharmaceuticals, Inc. |
Opened
110,000
|
$361,900,000 | 0.33% |
| Ironwood Pharmaceuticals Inc |
Opened
48,012
|
$313,038,000 | 0.29% |
| Acadia Pharmaceuticals Inc |
Opened
5,000
|
$81,250,000 | 0.07% |
| Surrozen Inc |
Opened
1,584
|
$17,345,000 | 0.02% |
| No transactions found | |||
| Showing first 500 out of 33 holdings | |||